AI Article Synopsis
- Benralizumab and mepolizumab are targeted therapies for severe eosinophilic asthma, acting on the IL-5 receptor and IL-5 to reduce inflammation.
- A proteomic study analyzed serum protein levels before and after treatment, identifying 22 proteins with significant changes that could indicate treatment response.
- Key proteins like CAYP1, A1AT, and A2M showed altered expressions post-therapy, suggesting they might serve as potential biomarkers for monitoring the effectiveness of these treatments in asthma patients.
Article Abstract
Benralizumab and mepolizumab are new therapies for severe eosinophilic asthma. They are both humanized IgG antibodies, targeting the IL-5 receptor and IL-5, respectively, suppressing the corresponding pathways. No specific biomarkers have been proposed to evaluate treatment response to benralizumab or mepolizumab. The aim of this proteomic study was to compare serum protein profiles of patients with severe eosinophilic asthma before and after anti-IL5 or anti-IL5R therapies. Proteomic analysis highlighted 22 differently abundant spots. Among the proteins identified, CAYP1, A1AT and A2M expression was significantly modified in both groups of patients after therapies while ceruloplasmin showed a significant modification in the group of benralizumab treatment. These differentially expressed proteins could be potential biomarkers of response to mepolizumab and benralizumab treatments and need further evaluation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00408-020-00379-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A systematic review of circulating IP-10/CXCL10 in patients with Plasmodium infections in relation to disease severity.
Sci Rep
December 2024
Medical Technology Program, Faculty of Science, Nakhon Phanom University, Nakhon Phanom, Thailand.
Interferon γ-induced protein 10 kDa (IP-10) or C-X-C motif chemokine 10 (CXCL10) is produced and secreted from specific leukocytes such as neutrophils, eosinophils, and monocytes, which play key roles in the immune response to Plasmodium infections. This systematic review aimed to collate and critically appraise the current evidence on IP-10 levels in malaria patients. It provided insights into its role in malaria pathogenesis and potential as a biomarker for Plasmodium infections and disease severity.
View Article and Find Full Text PDFIL-27 as a novel biomarker for pruritus in nodular prurigo and bullous pemphigoid.
Front Immunol
December 2024
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Introduction: Bullous pemphigoid (BP) and prurigo nodularis (PN) are chronic pruritic skin diseases that severely impact patients' quality of life. Despite the widespread attention these two diseases have garnered within the dermatological field, the specific pathogenesis, particularly the molecular mechanisms underlying the pruritus, remains largely unclear. Limited clinical sequencing studies focusing on BP and PN have hindered the identification of pathological mechanisms and the exploration of effective treatment strategies.
View Article and Find Full Text PDFEarly and Sustained Response to Benralizumab in Severe, Eosinophilic Asthma: A Real-World Observational Study.
J Asthma Allergy
December 2024
Pulmonology Clinic, Cantonal Hospital Graubünden, Chur, Switzerland.
Purpose: Although studies have evaluated benralizumab, a monoclonal IL-5 receptor α antibody in severe eosinophilic asthma (SEA), in real-world settings, additional evidence is needed to further characterize its effectiveness in specific patient populations. Our study aimed to evaluate asthma control over 56 weeks in patients treated with benralizumab in Swiss real-world settings.
Patients And Methods: Conducted across 13 centres, this prospective, observational, non-interventional study involved 73 adults with physician confirmed SEA.
Recalcitrant Pustular Dermatosis Successfully Treated With Prolonged Isotretinoin Therapy.
Cureus
November 2024
Dermatology, Imperial Dermatology, Hollywood, USA.
Isotretinoin (13-cis-retinoic acid) is a well-established systemic treatment for moderate to severe acne vulgaris, renowned for its ability to target multiple contributors to acne pathogenesis. However, its therapeutic potential extends beyond conventional acne management. This case report highlights its efficacy in treating recalcitrant pustular dermatosis, a condition that proved resistant to standard therapies and posed significant diagnostic challenges.
View Article and Find Full Text PDFChallenges With the Intolerance of Biologics in Severe Eosinophilic Asthma: The Risk of Exacerbations Is Time-Dependent With the Rise of Eosinophils.
Cureus
November 2024
Respiratory Diseases Clinic, Hospital Regional de Alta Especialidad de la Península de Yucatan, Merida, MEX.
Patients with severe eosinophilic asthma (SEA) can benefit from biologic therapy but some subjects may present an immune-mediated side effect. These patients will not meet the treatment goals and might have an increased risk of exacerbations. Monitoring these patients by determining blood eosinophil (BE) levels could be one of the tools that may allow a follow-up to prevent a worsening of asthma or exacerbations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!